94 related articles for article (PubMed ID: 7969046)
1. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.
Benchekroun MN; Schneider E; Safa AR; Townsend AJ; Sinha BK
Mol Pharmacol; 1994 Oct; 46(4):677-84. PubMed ID: 7969046
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance.
Sinha BK; Mimnaugh EG; Rajagopalan S; Myers CE
Cancer Res; 1989 Jul; 49(14):3844-8. PubMed ID: 2544260
[TBL] [Abstract][Full Text] [Related]
3. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
5. Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance.
Benchekroun NM; Myers CE; Sinha BK
Free Radic Biol Med; 1994 Sep; 17(3):191-200. PubMed ID: 7982624
[TBL] [Abstract][Full Text] [Related]
6. Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells.
Mimnaugh EG; Dusre L; Atwell J; Myers CE
Cancer Res; 1989 Jan; 49(1):8-15. PubMed ID: 2535695
[TBL] [Abstract][Full Text] [Related]
7. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
8. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
9. Anthracyclines.
Sinha BK; Politi PM
Cancer Chemother Biol Response Modif; 1990; 11():45-57. PubMed ID: 2223402
[TBL] [Abstract][Full Text] [Related]
10. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
11. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
12. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
13. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
15. Combined Fourier transform infrared and Raman spectroscopic approach for identification of multidrug resistance phenotype in cancer cell lines.
Krishna CM; Kegelaer G; Adt I; Rubin S; Kartha VB; Manfait M; Sockalingum GD
Biopolymers; 2006 Aug; 82(5):462-70. PubMed ID: 16493658
[TBL] [Abstract][Full Text] [Related]
16. DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues.
Dusre L; Rajagopalan S; Eliot HM; Covey JM; Sinha BK
Cancer Res; 1990 Feb; 50(3):648-52. PubMed ID: 2153443
[TBL] [Abstract][Full Text] [Related]
17. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
18. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
19. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance.
Samuels BL; Murray JL; Cohen MB; Safa AR; Sinha BK; Townsend AJ; Beckett MA; Weichselbaum RR
Cancer Res; 1991 Jan; 51(2):521-7. PubMed ID: 1845955
[TBL] [Abstract][Full Text] [Related]
20. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells.
Zampieri L; Bianchi P; Ruff P; Arbuthnot P
Anticancer Res; 2002; 22(4):2253-9. PubMed ID: 12174911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
